Medicare GLP-1 Bridge Program: What It Covers and Who Qualifies

The Medicare GLP-1 Bridge is a temporary CMS demonstration that runs from July 1, 2026 through December 31, 2027. It is designed to create a predictable copay for certain GLP-1 obesity medicines for eligible Part D enrollees. It is not the same as insurance coverage for type 2 diabetes medications, and it does not replace your normal Part D plan. Ask your plan or pharmacist whether they’re routing your GLP-1 claim through the Bridge rules or regular Part D.

Eligibility is based on age, BMI, and certain health conditions, and it requires prior authorization. The Bridge generally requires age 18+ and one of these: BMI at or above 35; or BMI at or above 30 with certain heart, kidney, or blood-pressure conditions; or BMI at or above 27 with prediabetes, prior stroke/heart attack, or symptomatic peripheral artery disease. If you already have type 2 diabetes or moderate-to-severe sleep apnea, you are generally covered through regular Part D instead of the Bridge. Your prescribing clinician can tell you which path your situation fits best.

The Bridge covers Wegovy (all forms), Foundayo, and Zepbound KwikPen. Wegovy includes injection forms and the Wegovy pill (oral semaglutide 25 mg), which is taken first thing in the morning with a small sip of water and at least 30 minutes before food, drinks, or other oral medicines. Foundayo (orforglipron) is a once-daily GLP-1 pill with no fasting or water restrictions and can be taken any time of day. Zepbound KwikPen is a multi-dose pen where one device holds a month of doses across all six strengths.

For eligible Part D enrollees, the Bridge sets a $50/month copay. That $50 does not count toward your Part D deductible or your out-of-pocket maximum. This can be helpful for predictable monthly costs, but it may not accelerate you toward other Part D thresholds the way normal cost-sharing might. For your exact situation, confirm with your plan or pharmacist before you fill.

The Bridge requires prior authorization, which usually means your plan needs documentation like BMI, relevant diagnoses, and prescribing notes. A practical step is to schedule a quick visit (or message) with your prescribing provider to confirm what diagnosis codes and recent measurements they’ll submit. If you’ve used GLP-1s before (including Ozempic, Wegovy, Mounjaro, Zepbound, or compounded versions), share your medication history and any side effects you had, so your clinician can document it clearly. If you are currently using a compounded GLP-1, ask your clinician how to document that history without assuming it will be treated the same as an FDA-approved product.

Some people will want to compare the Bridge copay with manufacturer self-pay or savings options for FDA-approved products. TrumpRx.gov is a federal site that lists the lowest manufacturer self-pay prices and routes you to the maker’s channel (like LillyDirect or NovoCare), but it is not insurance. At the time of writing, manufacturer cash prices and savings programs can change often and may have eligibility rules. Confirm current pricing and eligibility directly with the manufacturer, your plan, or your pharmacist before making decisions.